Smoldering Multiple Myeloma Clinical Trial
Official title:
Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
This is a randomized Phase II, open label, multi-centre study, with two independent arms.
Patients receive 6 injections of IPH2101, at the dose of 0.2 mg/kg or 2 mg/kg (according to
their randomization) administered over one hour infusion at four weeks intervals.
A patient whose disease achieves at least a minimal response to study treatment at any time
during the initial period of 6 cycles can be treated with an additional period of treatment
of 6 cycles.
Patients are followed 6 months after treatment completion or until a KIR occupancy level <
30% (i.e if the time required for KIR desaturation was > 6 months), whichever is longer.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00503763 -
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT02916771 -
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01955395 -
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
|
N/A | |
| Completed |
NCT01237054 -
Imaging in MGUS, SMM and MM
|
Phase 2 | |
| Completed |
NCT02903381 -
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03301220 -
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
|
Phase 3 | |
| Active, not recruiting |
NCT03236428 -
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01718899 -
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00099047 -
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
Phase 2 | |
| Completed |
NCT00112827 -
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
|
Phase 1/Phase 2 | |
| Terminated |
NCT01248455 -
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03289299 -
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT06365060 -
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
|
||
| Active, not recruiting |
NCT02415413 -
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01302886 -
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05841550 -
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06183489 -
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Active, not recruiting |
NCT02886065 -
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
|
Phase 1 | |
| Withdrawn |
NCT01571726 -
Imaging Studies and the Development of Multiple Myeloma
|
Phase 2 |